What is sitagliptin? What is sitagliptin used for?

Sitagliptin is an oral drug that reduces blood sugar (glucose) levels in patients with type 2 diabetes. Sitagliptin is indicated as an adjunct to diet and exercise.

Sitagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.

Sitagliptin has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using sitagliptin.

Sitagliptin is a member of a class of drugs that inhibit the enzyme, dipeptidyl peptidase-4 (DPP-4) and are therefore called DPP-4 inhibitors. Other members of the class include saxagliptin (Onglyza) and linagliptin (Tradjenta) Following a meal, incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released from the intestine, and their levels increase in the blood. GLP-1 and GIP reduce blood glucose by increasing the production and release of insulin from the pancreas. GLP-1 also reduces blood glucose by reducing the secretion by the pancreas of the hormone, glucagon, a hormone that increases the production of glucose by the liver and raises the blood level of glucose. The net effect of increased release of GLP-1 and GIP is to reduce blood glucose levels. Sitagliptin inhibits the enzyme, DPP-4, that destroys GLP-1 and GIP and thereby increases the levels and activity of both hormones. As a result, blood glucose levels fall. In summary, sitagliptin reduces blood glucose levels by inhibiting DPP-4 and increasing the levels of GLP-1 and GIP. Sitagliptin was approved by the FDA in October 2006.

What brand names are available for sitagliptin?

Januvia

Is sitagliptin available as a generic drug?

No

Do I need a prescription for sitagliptin?

Yes

What are the side effects of sitagliptin?

WARNING

  • There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue sitagliptin.
  • There have been postmarketing reports of acute renal failure, sometimes requiring dialysis. Dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with ESRD. Assessment of renal function is recommended prior to initiating sitagliptin and periodically thereafter.
  • There is an increased risk of hypoglycemia when sitagliptin is added to an insulin secretagogue (e.g., sulfonylurea) or insulin therapy. Consider lowering the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia.
  • There have been postmarketing reports of serious allergic and hypersensitivity reactions in patients treated with sitagliptin such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. In such cases, promptly stop sitagliptin, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes.
  • There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with sitagliptin or any other anti-diabetic drug.

Common side effects

The most common side effects of sitagliptin are:

Other important side effects of sitagliptin include:

SLIDESHOW

Type 2 Diabetes Diagnosis, Treatment, Medication See Slideshow

What is the dosage for sitagliptin?

Sitagliptin may be taken with or without food. The recommended dose is 100 mg once daily. Renal function should be assessed prior to starting sitagliptin and periodically during treatment. The dose of sitagliptin should be modified based on renal function.

Which drugs or supplements interact with sitagliptin?

Sitagliptin may slightly increase the concentration of digoxin (Lanoxin) in the body when both drugs are being taken. Digoxin concentrations should be monitored appropriately. The occurrence of low blood glucose increases when sitagliptin is combined with a sulfonylurea (for example, glyburide [Micronase, Diabeta, Glynase, Prestab]) or insulin. The dose of insulin or sulfonylurea should be reduced.

Is sitagliptin safe to take if I'm pregnant or breastfeeding?

There are no adequate studies of sitagliptin in pregnant women.

It is unknown whether sitagliptin is secreted in human breast milk.

What else should I know about sitagliptin?

What preparations of sitagliptin are available?

Tablets: 25, 50, and 100 mg

How should I keep sitagliptin stored?

Tablets should be stored at room temperature, 15-30 C (59-86 F)

QUESTION

______________ is another term for type 2 diabetes. See Answer

Summary

Sitagliptin (Januvia) is a medication prescribed for the treatment of type 2 diabetes. Januvia is combined with exercise and diet to improve blood glucose levels in individuals with type 2 diabetes. Side effects, drug interactions, warnings and precautions, and pregnancy information should be reviewed prior to taking this medication.

Treatment & Diagnosis

Medications & Supplements

Prevention & Wellness

Subscribe to MedicineNet's Diabetes Newsletter

By clicking "Submit," I agree to the MedicineNet Terms and Conditions and Privacy Policy. I also agree to receive emails from MedicineNet and I understand that I may opt out of MedicineNet subscriptions at any time.

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

See more info: sitagliptin on RxList
Medically Reviewed on 6/28/2019
References
FDA Prescribing Information
CONTINUE SCROLLING FOR RELATED SLIDESHOW